(21) demonstrated through in vitro transformation assays using primary mouse neural crest cells (NCCs) that MYCN-driven carcinogenesis differentially transforms NCCs with ARID1A deletion compared to those with random 1p36 deletions, thereby identifying ARID1A as a MYCN-specific tumor suppressor. This evidence concerns the gene ARID1A and neoplasm.